RxDoctor Payments Data

Phyllis Grable Esposito, MD

Neurology · Hartford, CTNPI 1922134634

Payments from drug & device makers

$8,838in general payments, 2019–2025

Across 514 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$763
  • Amgen$578
  • Pfizer$548
  • EMD Serono, Inc.$409
  • UCB, Inc.$388
  • plus $5K from 49 others

What the payments were for

  • Speaking & faculty fees$1492%
  • Food & beverage$8,60997%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)96$1,193
Novartis55$763
Amgen(2 entities)27$578
Pfizer45$548
EMD Serono, Inc.19$409
UCB, Inc.16$388
Teva Pharmaceuticals USA, Inc.35$319
Sanofi15$286
Biogen12$264
SK Life Science, Inc.11$213
Lundbeck LLC8$193
Eisai Inc.9$187
TG Therapeutics, Inc.6$186
Bristol Myers Squibb8$170
Amneal Pharmaceuticals LLC11$165
Grifols USA, LLC8$157
CSL Behring6$157
Acorda Therapeutics, Inc10$149
Takeda Pharmaceuticals U.S.A., Inc.6$141
AstraZeneca(2 entities)6$129
Avanir Pharmaceuticals, Inc.8$126
Genentech USA, Inc.5$123
Sunovion Pharmaceuticals Inc.7$114
Otsuka Pharmaceutical Development & Commercialization, Inc.1$112
Noctrix Health, Inc.1$110
Acadia Pharmaceuticals Inc6$107
Mallinckrodt Enterprises LLC5$94
Adamas Pharmaceuticals, Inc.5$92
Supernus Pharmaceuticals, Inc.6$89
Lilly USA, LLC4$76
Neurelis, Inc.3$74
GE HealthCare3$73
Akcea Therapeutics, Inc.3$72
MDD US Operations, LLC4$69
Arbor Pharmaceuticals, Inc.3$67
Assertio Therapeutics, Inc.4$65
Biohaven Pharmaceutical Holding Company Ltd.3$65
Vanda Pharmaceuticals Inc.2$63
Catalyst Pharmaceuticals, Inc.3$63
Upsher-smith Laboratories LLC2$55
Otsuka America Pharmaceutical, Inc.2$55
Octapharma USA, Inc.2$54
Neurocrine Biosciences, Inc.2$50
Cycle Pharmaceuticals Inc2$48
Axsome Therapeutics, Inc.2$40
Kyowa Kirin, Inc.2$38
Tanabe Pharma America, Inc.2$38
Strongbridge US Inc.3$37
Alnylam Pharmaceuticals Inc.2$34
Medtronic2$29
Xeris Pharmaceuticals, Inc.2$27
Scilex Pharmaceuticals Inc.1$24
Vertical Pharmaceuticals, LLC1$24
Johnson & Johnson1$20
Collegium Pharmaceutical, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,838 in reported general payments places this provider in the 65th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$119,568
Medicare patients
378
Services billed
988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine23$349,145
CopaxoneGlatiramer Acetate17$150,993
NuplazidPimavanserin Tartrate13$62,684
RytaryCarbidopa/Levodopa20$40,115
Nurtec OdtRimegepant Sulfate25$29,236
NeuproRotigotine16$29,038
QuliptaAtogepant18$28,785
Ajovy SyringeFremanezumab-Vfrm16$15,763
Carbamazepine ErCarbamazepine90$9,413
Gabapentin300$7,456
Carbidopa-LevodopaCarbidopa/Levodopa168$4,658
Oxcarbazepine37$3,904
Levetiracetam69$2,981
Depakote SprinkleDivalproex Sodium13$2,926
Divalproex Sodium57$2,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$548$378,38148 claims
Teva Pharmaceuticals USA, Inc.Copaxone$319$150,99317 claims
Acadia Pharmaceuticals IncNuplazid$107$62,68413 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$165$40,54633 claims
UCB, Inc.Neupro$388$29,03816 claims
AbbVieQulipta$1,193$28,78518 claims
Upsher-smith Laboratories LLCTopiramate$55$1,542100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 280 neurology providers in Connecticut.

Other neurology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →